INSR and cancer: IGF-1 receptor (IGF-1R) is not mutated in most cancers and has a high degree of structural homology with insulin receptor (INSR), particularly in the tyrosine domain, which can form a heterodimer with each other and signal through many common mediators, but the two receptor signaling axes exhibit marked functional variance (7, 8).